Brandywine Global Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

Brandywine Global Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,195	Closed	-$122K	–	751
2023 Q2	$122K	Sell	1,195 -9	-0.7%	-$1.24K	﹤0.01%	673
2023 Q1	$213K	Hold	1,204	–	–	﹤0.01%	679
2022 Q4	$465K	Hold	1,204	–	–	﹤0.01%	680
2022 Q3	$406K	Sell	1,204 -46	-4%	-$16.7K	﹤0.01%	685
2022 Q2	$411K	Sell	1,250 -183	-13%	-$64.2K	﹤0.01%	671
2022 Q1	$627K	Hold	1,433	–	–	﹤0.01%	646
2021 Q4	$628K	Sell	1,433 -467	-25%	-$235K	﹤0.01%	606
2021 Q3	$1.06M	Buy	+1,900	New	+$953K	0.01%	569

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Brandywine Global Investment Management's TVRD Position: Q3 2023 in Review

Brandywine Global Investment Management sold out of Tvardi Therapeutics (TVRD) in Q3 2023, closing a stake of 1,195 shares — an estimated $122K sold.

Brandywine Global Investment Management first reported a position in TVRD in Q3 2021 and held it in 8 quarters. The position peaked at $1.06M in Q3 2021. 122 funds tracked by Wall St. Rank hold TVRD as of Q3 2023.

Brandywine Global Investment Management reported no remaining Tvardi Therapeutics position as of Q3 2023 after selling out during the quarter.
Brandywine Global Investment Management sold 1,195 Tvardi Therapeutics shares in Q3 2023, an estimated $122K.
Brandywine Global Investment Management first reported a position in Tvardi Therapeutics in Q3 2021 and held it in 8 quarters.
Brandywine Global Investment Management's Tvardi Therapeutics position peaked at $1.06M in Q3 2021.
122 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2023.

Based on Brandywine Global Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.